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Abstract: A growing number of studies suggest a tumor suppressive role and potential prognostic signif-icance of miR-
30a-3p in different types of cancer. However, relatively few studies have focused on this microRNA in neoplastic thyroid 
lesions, including papillary thyroid cancer (PTC). The aim of our study was to shed more light on the potential involvement 
and clinical relevance of miR-30a-3p in this type of cancer. We examined the expression levels of this microRNA in 42 pairs 
of PTCs and matched non-tumor thyroid tissues using quantitative RT-PCR. We analyzed their association with clinical 
and histopathological parameters. The results revealed that miR-30a-3p was significant-ly downregulated in the majority of 
PTC tissues compared to corresponding non-tumor tissues. Moreover, decreased expression of miR-30a-3p was associated 
with advanced clinical stage, pres-ence of multiple tumor foci and capsular invasion, suggesting a role in aggressive disease. 
Although the role of this microRNA and its prognostic utility remain to be elucidated, the presented data sug-gest that 
downregulated expression of miR-30a-3p indicates poorer prognosis in PTC patients, war-ranting further investigations.
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INTRODUCTION
Papillary thyroid cancer (PTC) is the most prevalent 
type of thyroid malignancies, accounting for 75-85% 
of all thyroid cancer cases. Over the last decades, the 
incidence of thyroid cancer has been increasing all 
over the world, and this increase is mainly due to an 
increase in PTC incidence [1,2]. Risk stratification of 
PTC patients is currently based on clinicopathological 
characteristics such as age, gender, tumor size, extra-
thyroidal spread, nodal metastases, distant metastases 
and clinical stage. Although this approach is reliable 
in predicting the mortality risk, it has proved to be 
uncertain in predicting the risk of recurrence, which 
occurs more often than death from PTC, so it is more 
clinically relevant [3,4]. Therefore, the stratification 
of PTC patients into low- and high-risk prognostic 
groups still needs to be improved in order to accurately 
tailor management. Better understanding of molecular 
mechanisms of PTC occurrence and progression may 
be helpful in the identification of novel diagnostic and 
prognostic biomarkers as well as potential therapeutic 
targets for the treatment of more aggressive and/or 
advanced PTC cases.
A number of studies in the past two decades have 
demonstrated the importance of microRNAs (miRNAs 
or miRs) in cancer biology. MiRNAs are small, non-
coding RNAs (consisting of  ~ 22 nucleotides) involved 
in the posttranscriptional regulation of gene expression. 
MiRNAs can modulate target gene expression negatively 
by binding to the 3’-untranslated region of mRNAs, 
leading to their degradation or inhibition of translation 
[5]. Aberrant expression of different microRNAs has 
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been associated with processes such as tumor growth, 
invasion, angiogenesis, metastasis and immune eva-
sion. Depending on their target genes, microRNAs 
can function as oncogenes or tumor suppressors [5,6].
One of the microRNAs with potential tumor sup-
pressor activity that is frequently found to be deregu-
lated and associated with aggressive tumor features and 
progression in various human cancers is miR-30a-3p. 
So far, downregulated expression of this member of 
the miR-30 family has been reported in lung cancer 
[7-10], breast cancer [11-13], colorectal cancer [14], 
bladder cancer [15], ovarian cancer [16], endometrial 
cancer [17], hepatocellular carcinoma [18], hematologic 
malignancies [19] and others.
The aim of this study was to investigate the expres-
sion levels of miR-30a-3p in papillary thyroid cancer 
and corresponding non-tumor thyroid tissue, and to 
evaluate the association with clinical and pathological 
parameters in order to determine the potential sig-
nificance of miR-30a-3p in PTC malignancy. To our 
knowledge, this is one of only a few studies of miR-
30a-3p expression in this type of cancer.
MATERIALS AND METHODS
Patients and clinicopathological characteristics
Tissue samples (paired tumor and corresponding non-
tumor thyroid tissues) were obtained from 42 patients 
with PTC, following surgical excision at the Center for 
Endocrine Surgery, Clinical Center of Serbia, between 
2012 and 2015. Samples were snap-frozen in liquid ni-
trogen and stored at -70°C until RNA extraction. Clinical 
and histopathological parameters are shown in Supple-
mentary Table S1. All patients included in the study gave 
their informed consent. The study was approved by the 
Ethics Committee of Clinical Center of Serbia.
RNA extraction and reverse transcription
Total RNA extraction from tumor and non-tumor thy-
roid tissues was performed using TRI Reagent Solution 
(Ambion, Foster City, CA) according to manufacturer’s 
instructions, following homogenization in liquid ni-
trogen. RNA quantification was done on NanoDrop™ 
1000 (Thermo Fisher Scientific, USA). Next, 10 ng of 
total RNA was reverse transcribed using a TaqMan 
Micro-RNA Reverse Transcription Kit and specific 
stem-loop RT primer from TaqMan miR-30a-3p Assay 
(ID 000416), according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA). Small nuclear 
RNA (nRNA) RNU6B (Assay ID 001093) was used as 
an endogenous control.
Quantitative PCR (qPCR)
RT-qPCR was performed on a 7500 Real Time PCR 
System (Applied Biosystems, Foster City, CA). PCR 
reactions were carried out in a 20-µL reaction volume 
using the TaqMan Universal Master Mix, No Amperase 
UNG (Applied Biosystems, Warrington, UK), specific 
TaqMan miR-30a-3p assay (ID 000416) or small nRNA 
RNU6B assay (ID 001093), which was used for nor-
malization. The cycling conditions were as follows: 10 
min at 95°C, 40 cycles of 15 s at 95°C and 60 s at 60°C.
Ct values were calculated using Applied Biosys-
tems 7500 system SDS software. The relative quantity 
of target microRNA in each tumor sample (T) was 
expressed as the fold change relative to the correspond-
ing non-tumor tissue sample (N) and normalized to 
the internal reference RNU6B according to the 2-ΔΔCt 
method, following the equation:
T/N=2-ΔΔCt, ΔΔCt=ΔCt(T)- ΔCt(N),  
ΔCt=Cttarget-Ctendogenous control.
In order to compare the relative expression level 
between tumor and non-tumor tissue, the relative 
quantity of target in each sample was expressed as fold 
change relative to the calibrator (1x sample, a sample 





Statistical analysis was performed using the GraphPad 
Prism 5.01 (GraphPad Software). Nonparametric tests, 
Mann-Whitney U test and Spearman’s correlation test, 
were used for the analysis of the association of miR-30a-
3p expression levels with clinical and histopathological 
parameters, since a non-Gaussian distribution of the 
expression values was detected. The significance of the 
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difference between pairs of tumor and non-tumor tissues 
was evaluated by the Wilcoxon matched-pairs test. Clas-
sification of the fold change values between tumor and 
corresponding non-tumor thyroid tissues was based on 
the following criteria: fold change >1 as “increased”; fold 
change <1 as “decreased”. P≤0.05 represented statistical 
significance, P<0.1 represented a statistical trend.
RESULTS
The expression level of miR-30a-3p in PTC and 
non-tumor thyroid tissues
The overall expression level of miR-30a-3p in tumor 
and non-tumor thyroid samples is shown in Fig. 1A. 
There was a significant difference in miR-30a-3p ex-
pression between tumor and corresponding non-tumor 
thyroid tissues (P=0.002). Most of the tumor samples 
(33/42; 79%) showed a significantly decreased level of 
miR-30a-3p compared to matched non-tumor samples 
(P<0.0001), as shown in Fig. 1B.
Relationship between miR-30a-3p expression and 
clinical and pathological characteristics
The expression levels of miR-30a-3p in PTC with 
respect to standard clinicopathological parameters 
are presented in Table 1. A significant association 
Fig. 1. The expression level of miR-30a-3p in PTC and non-tumor 
thyroid tissues. A– miR-30a-3p expression is deregulated in PTC 
tissues compared to matched non-tumor thyroid tissues. Paired 
PTC and corresponding non-tumor tissues are connected with lines. 
B– 78.6% (33/42) of PTCs had significantly decreased expression 
of miR-30a-3p; 21.4% (9/42) had an increased expression in PTC 
compared to matched non-tumor thyroid tissue. The dots represent 
patients with the decreased miR-30a-3p expression in tumor tis-
sue while squares represent patients with an increased expression. 
Statistical analyses were performed by Wilcoxon matched pairs 
test and P<0.05 was considered statistically significant.
Table 1. The association of miR-30a-3p expression level with 




relative expression P value
Gender
Male (n=10) 0.572 (0.141–0.959)
0.585
Female (n=32) 0.507 (0.270–0.934)
Age Corr.Coef. -0.233 0.142
≤45 (n=26) 0.660 (0.397–1.043)
0.096*
>45 (n=15) 0.378 (0.228–0.726)
Tumor size (cm) Corr.Coef. -0.033 0.834
Histovariant
Classic (n=17) 0.404 (0.225–0.660)
0.099*
Follicular+other (n=19) 0.778 (0.234–1.109)
Tumor focality
Multifocal (n=13) 0.376 (0.179–0.610)
0.024
Monofocal (n=28) 0.660 (0.386–1.004)
pT category
pT1+2 (n=21) 0.600 (0.305–1.101)
0.352
pT3+4 (n=21) 0.488 (0.231–0.801)
Lymph node metastases
Yes (n=11) 0.494 (0.378–0.798)
0.841
No (n=31) 0.600 (0.228–1.022)
Capsular invasion
Yes (n=22) 0.392 (0.204–0.736)
0.029
No (n=20) 0.801 (0.408–1.075)
Vascular invasion
Yes (n=15) 0.600 (0.228–0.883)
0.989
No (n=26) 0.504 (0.340–0.968)
Extrathyroidal spread
Yes (n=9) 0.381 (0.188–0.691)
0.191
No (n=32) 0.632 (0.269–1.004)
Clinical stage Corr.Coef. -0.471 0.002
I+II (n=35) 0.657 (0.376–1.022)
0.011
III (n=7) 0.364 (0.139–0.381)
The data are presented as the median with interquartile range and analyzed 
by Man-Whitney U test or Spearman’s correlation test. Significant P values 
are shown in bold and the statistical trend is marked with an asterisk. 
miR-30a-3p relative expression represents the expression fold change in 
tumor tissue compared to matched non-tumor tissue.
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of decreased miR-30a-3p was found with advanced 
clinical stage (P=0.011), which was also supported 
by the presence of a significant negative correlation 
between miR-30a-3p relative expression levels and stage 
(P=0.002, r=-0.471), obtained by Spearman’s correla-
tion test. Lower miR-30a-3p levels were also signifi-
cantly associated with the presence of multiple tumor 
foci (P=0.024) and with capsular invasion (P=0.029). 
No other significant associations were detected.
DISCUSSION
MicroRNAs have been proposed by numerous studies 
as promising diagnostic, prognostic, therapeutic and 
surveillance tools for human cancers because of their 
critical roles in various biological processes during 
tumor development and progression [20-25].
In vitro studies have shown that miR-30a-3p is 
involved in the regulation of cell proliferation, angio-
genesis, cell migration, invasiveness, epithelial-mesen-
chymal transition (EMT) and apoptosis [11,18,26,27]. 
Interestingly, one of the targets experimentally con-
firmed to be negatively regulated by miR-30a-3p is 
C-jun-amino-terminal kinase-interacting protein 4 
(SPAG9), a scaffold protein that activates the mitogen-
activated protein kinase (MAPK) signaling pathway 
in tumorigenesis, leading to cell proliferation and 
inhibition of apoptosis [28]. Constitutive activation of 
the MAPK signaling pathway is frequently found in 
PTC [29]. Pathway activation is caused by mutations 
in proto-oncogene B-Raf (BRAF) or one of the RAS 
family genes, or by RET/PTC rearrangements in 70% 
of cases [30]. Other PTC cases do not harbor any of 
these genetic alterations suggesting that some other 
mechanisms, including microRNAs might be involved.
To date, aberrant expression of miR-30a-3p has 
been detected in various types of cancer, but relatively 
few studies have investigated the biological role or 
the clinical relevance of this microRNA in neoplastic 
thyroid lesions including PTC [31,32].
To shed more light on the involvement of miR-30a-
3p and its clinical relevance in PTC, we investigated 
the level of expression of this microRNA in matched 
tumor/non-tumor tissue samples and its association 
with clinical and pathological parameters. The results 
of the present study show that miR-30a-3p expression 
is significantly downregulated in PTC tissues compared 
to corresponding non-tumor thyroid tissues in the 
majority of analyzed samples, suggesting a potential 
involvement of this microRNA in PTC development 
and/or progression. This is in line with the results 
of other studies of miR-30a-3p in PTC. miR-30a-3p 
is significantly downregulated in PTC compared to 
adjacent non-tumor tissue and to benign goiter tis-
sue [31]. Next-generation sequencing and expression 
analysis of miRNAs in PTC and contralateral normal 
thyroid tissue specimens revealed miR-30a-3p to be 
among the most abundantly downregulated miRNAs 
in PTC [32]. Significantly decreased level of miR-
30a-3p in tumor tissue compared to corresponding 
non-tumor tissue was also found in lung carcinoma 
[7,8,10,26], esophageal carcinoma [27], gastric cancer 
[28], colorectal cancer [14] and liver cancer [18].
Our analysis showed that a decreased expression of 
miR-30a-3p was significantly associated with advanced 
clinical stage (according to the TNM staging system), 
the presence of multiple tumor foci and capsular inva-
sion. We also detected a trend towards the association 
with classical papillary growth pattern and older age. 
Findings suggest that multiple foci in PTC represent 
intraglandular metastatic spread [33] and multifocal-
ity was associated with extrathyroidal spread, nodal 
metastases, advanced disease and recurrence [34,35]. 
Although classical and follicular histovariants of PTC 
are currently categorized into the same risk group 
[36,37], some evidence suggest that a classical hist-
ovariant is associated with higher risk of aggressive 
behavior and worse prognosis [38,39]. Also, accord-
ing to the thyroid differentiation score determined in 
the Cancer Genome Atlas (TCGA) study of thyroid 
cancers, although both histologic variants are well 
differentiated, it was found that the classical histovari-
ant is less differentiated than the follicular variant 
[40,41]. Considering all this, our results show that a 
decreased expression of miR-30a-3p is in correlation 
with more aggressive tumor features. These results are 
in accordance with the results of other studies of this 
microRNA in various cancers. A significant difference 
in the expression of miR-30a-3p in high invasive PTC 
(present lateral lymph node metastasis) compared to 
low invasive PTC (no lymph node metastasis), with a 
trend towards association with tumor multifocality was 
described [31]. In other types of cancer, miR-30a-3p 
downregulation was associated with advanced stage 
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and more aggressive tumor features such as tumor 
size, pT category, nodal metastases, TNM stage in 
lung cancer [8], with higher tumor grade and poorer 
differentiation in ovarian cancer [16,42], vascular 
invasion in hepatocellular carcinoma [18], distant 
metastases in lung and renal carcinoma [43,44] and 
shorter progression free or overall survival in many 
of them [8,11-13,28,42].
Although the data presented herein need to be 
confirmed in larger cohorts, they demonstrate that 
miR-30a-3p expression is deregulated in PTC and 
that the decreased expression of this microRNA is 
associated with more aggressive tumor features and 
advanced disease stage, which supports its potential 
usefulness in identifying PTC patients at higher risk for 
disease progression. The exact role of miR-30a-3p, its 
potential involvement in the regulation of the MAPK 
signaling pathway, as well as its utility as a diagnostic 
and/or prognostic tool, remain to be elucidated.
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